Tech Company Financing Transactions
Life Biosciences Funding Round
On 4/8/2026, Life Biosciences raised $80 million in Series D funding from private investors.
Transaction Overview
Company Name
Announced On
4/8/2026
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series D
Investors
Proceeds Purpose
The proceeds will support the company's operations into the second half of 2027, including the completion of its recently initiated Phase 1 clinical trial of ER-100 and the continued advancement of its broader Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Park Plaza, Level Three
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
At Life Biosciences, we are on a mission to reverse and prevent age-related diseases. Our platform, termed partial epigenetic reprogramming, has been shown to rejuvenate cells in preclinical models with profound therapeutic effect. It has the potential to rejuvenate cells and restore function in many age-related diseases. We are the sole company with intellectual property covering the therapeutic use of our partial epigenetic reprogramming technology. We are also the only company to have received FDA approval to advance this technology into human clinical studies. While our initial clinical trial is for optic neuropathies, our science has the potential to bring tremendous benefit to patients suffering from multiple age-related diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 4/8/2026: Treon venture capital transaction
Next: 4/8/2026: Patlytics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








